We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Moderna is claiming a phase 3 win based on interim trial data for its investigational mRNA-1345 vaccine targeting respiratory syncytial virus (RSV). Read More
In the ongoing battle of pro-life groups vs. the government on access to the so-called abortion pill, the FDA is pressing a Texas judge to reject a request by anti-abortion groups for a court order withdrawing federal approval for the drug. Read More
AbbVie and Eli Lilly have pulled out of a voluntary UK drug pricing agreement for the National Health Service (NHS) — a move that could leave NHS patients with curtailed access to their therapies. Read More
Last year’s decision by HHS to limit payment for Biogen’s controversial Alzheimer’s drug Aduhelm to patients in a clinical trial could have a long-term negative effect on the entire accelerated approval (AA) pathway, said former FDA Commissioner Scott Gottlieb. Read More
Oncology drug trials should consider a wide range of dosages and how they impact a wide variety of participants, rather than immediately titrating patients up to the maximum tolerated dose (MTD), the FDA said in a new draft guidance. Read More
Astellas Pharma has filed a federal lawsuit accusing China’s Qilu Pharma of infringing on its patent protections for the blockbuster overactive bladder drug Myrbetriq (mirabegron) by preparing a generic version. Read More
Reforms in orphan drug exclusivity will see significant movement in 2023, according to Andi Fristedt, the FDA’s deputy commissioner for policy, legislation, and international affairs. Read More
The European Medicines Agency (EMA)’s safety committee has recommended measures to reduce the serious side effects linked with Janus kinase (JAK) inhibitors used to treat chronic inflammatory disorders. Read More
California is taking to the courts to challenge insulin pricing, charging that Eli Lilly, Novo Nordisk, Sanofi and three pharmacy benefit managers (PBMs) have conspired to set the price of insulin and to keep it on an ever-increasing trajectory. Read More